Associated Genetic Biomarkers
There are 2 clinical trials for brain metastasis, of which 0 are open and 2 are completed or closed. Of the trials that contain brain metastasis as an inclusion criterion, 1 is phase 2 (0 open) and 1 is phase 3 (0 open).
ERBB2 is the most frequent gene inclusion criterion for brain metastasis clinical trials .
Cabazitaxel, lapatinib, and memantine are the most common interventions in brain metastasis clinical trials.
Significant Genes in Brain Metastasis
ERBB2 is an inclusion eligibility criterion in 1 clinical trial for brain metastasis, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 status and brain metastasis as inclusion criteria, 1 is phase 2 (0 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.